Chugai Pharmaceutical is paying PharmaMar €30 million ($31.4 million) upfront for Japanese rights to the latter’s Phase III-stage, marine-derived anticancer drug PM1183 (lurbinectedin). The RNA polymerase II inhibitor is in development for the...
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Chugai Pharmaceuticals (4519-TO):